EE200300408A - Aktiivsete valkude saagise suurendamine - Google Patents

Aktiivsete valkude saagise suurendamine

Info

Publication number
EE200300408A
EE200300408A EEP200300408A EEP200300408A EE200300408A EE 200300408 A EE200300408 A EE 200300408A EE P200300408 A EEP200300408 A EE P200300408A EE P200300408 A EEP200300408 A EE P200300408A EE 200300408 A EE200300408 A EE 200300408A
Authority
EE
Estonia
Prior art keywords
increasing
yield
active proteins
proteins
preparations
Prior art date
Application number
EEP200300408A
Other languages
English (en)
Estonian (et)
Inventor
M. Sassenfeld Helmut
L. Remmele Richard Jr.
E. Mccoy Rebecca
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of EE200300408A publication Critical patent/EE200300408A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Measurement Of Radiation (AREA)
EEP200300408A 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine EE200300408A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103301P 2001-02-23 2001-02-23
PCT/US2002/005645 WO2002068455A2 (fr) 2001-02-23 2002-02-22 Augmentation du taux de recuperation de proteines actives

Publications (1)

Publication Number Publication Date
EE200300408A true EE200300408A (et) 2003-12-15

Family

ID=23033913

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300408A EE200300408A (et) 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine

Country Status (21)

Country Link
US (2) US7157557B2 (fr)
EP (1) EP1366062B1 (fr)
JP (1) JP2005505494A (fr)
KR (1) KR20040052481A (fr)
CN (1) CN1547586A (fr)
AT (1) ATE517909T1 (fr)
AU (1) AU2002255600B2 (fr)
BG (1) BG108087A (fr)
CA (1) CA2438094C (fr)
CZ (1) CZ20032208A3 (fr)
EE (1) EE200300408A (fr)
ES (1) ES2370235T3 (fr)
HK (1) HK1059267A1 (fr)
HU (1) HUP0303246A2 (fr)
IL (1) IL157446A0 (fr)
MX (1) MXPA03007563A (fr)
PL (1) PL374045A1 (fr)
RU (1) RU2316563C2 (fr)
SK (1) SK10472003A3 (fr)
WO (1) WO2002068455A2 (fr)
ZA (1) ZA200305909B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517909T1 (de) * 2001-02-23 2011-08-15 Immunex Corp Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
EP1660094A4 (fr) 2003-08-26 2009-09-16 Univ Colorado Inhibiteurs de l'activite de la protease serine et leurs utilisations dans des methodes et preparations de traitement d'infections bacteriennes
WO2006060083A1 (fr) * 2004-10-22 2006-06-08 Amgen Inc. Methodes de repliement de polypeptides
BRPI0517457A (pt) * 2004-10-22 2008-10-07 Amgen Inc métodos para reenovelamento de anticorpos recombinantes
EP1844069A4 (fr) * 2005-01-28 2009-05-20 Apollo Life Sciences Ltd Molécules et leurs molécules chimériques
MX2007014148A (es) 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
BRPI0713252C1 (pt) 2006-07-14 2021-05-25 Genentech Inc processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
CA2691692C (fr) 2007-07-09 2021-05-18 Genentech, Inc. Prevention de la reduction des liaisons disulfure au cours de la production recombinante de polypeptides
WO2009036209A2 (fr) * 2007-09-14 2009-03-19 Amgen Inc. Populations d'anticorps homogènes
CN102482321B (zh) 2009-06-22 2015-06-17 安姆根有限公司 使用化学控制的氧化还原态重折叠蛋白质
CA2765154A1 (fr) 2009-06-25 2010-12-29 Amgen Inc. Procedes de purification par capture de proteines exprimees dans un systeme non mammifere
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
WO2011068993A1 (fr) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
JP6216921B2 (ja) 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
EP2802653A4 (fr) 2012-01-10 2015-09-02 Univ Colorado Regents Compositions de molécules de fusion de l'alpha-1 antitrypsine, procédés et utilisations associés
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
EP2880169B1 (fr) 2012-08-02 2017-05-17 F. Hoffmann-La Roche AG Procédé de production de molécules monomères et multimères et leurs utilisations
WO2014043103A1 (fr) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Étanercept correctement replié de pureté élevée avec un excellent rendement
WO2014137903A2 (fr) 2013-03-08 2014-09-12 Genzyme Corporation Fabrication continue intégrée de substances de médicament de protéine thérapeutique
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
WO2018075818A1 (fr) 2016-10-21 2018-04-26 Amgen Inc. Formulations pharmaceutiques et leurs procédés de préparation
EP3843869A1 (fr) 2018-08-31 2021-07-07 Genzyme Corporation Résine de chromatographie stérile et son utilisation dans des procédés de fabrication
JP2022512636A (ja) 2018-10-11 2022-02-07 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4766205A (en) 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4970067A (en) * 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU648214B2 (en) * 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
HUT72926A (en) * 1993-08-04 1996-06-28 Ciba Geigy Ag High molecular weight desulphatohirudin
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
AU2603995A (en) 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
CA2195665A1 (fr) * 1994-07-22 1996-02-08 Robert Frederick Geoffrey Booth Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
ATE517909T1 (de) * 2001-02-23 2011-08-15 Immunex Corp Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen

Also Published As

Publication number Publication date
CA2438094A1 (fr) 2002-09-06
AU2002255600B2 (en) 2008-01-24
US20020182665A1 (en) 2002-12-05
WO2002068455A2 (fr) 2002-09-06
JP2005505494A (ja) 2005-02-24
CN1547586A (zh) 2004-11-17
ATE517909T1 (de) 2011-08-15
CA2438094C (fr) 2011-10-11
RU2316563C2 (ru) 2008-02-10
EP1366062A2 (fr) 2003-12-03
ZA200305909B (en) 2004-06-04
US20070270577A1 (en) 2007-11-22
US7157557B2 (en) 2007-01-02
IL157446A0 (en) 2004-03-28
SK10472003A3 (sk) 2004-03-02
BG108087A (bg) 2005-04-30
HUP0303246A2 (hu) 2003-12-29
CZ20032208A3 (cs) 2004-01-14
PL374045A1 (en) 2005-09-19
WO2002068455A3 (fr) 2003-09-18
RU2003127830A (ru) 2005-04-10
US7544784B2 (en) 2009-06-09
MXPA03007563A (es) 2003-12-11
HK1059267A1 (en) 2004-06-25
KR20040052481A (ko) 2004-06-23
ES2370235T3 (es) 2011-12-13
EP1366062B1 (fr) 2011-07-27

Similar Documents

Publication Publication Date Title
EE200300408A (et) Aktiivsete valkude saagise suurendamine
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
DE602004011770D1 (de) Fusionsproteine
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DE60037450D1 (de) Funf-helix protein
EP2298331A3 (fr) Utilisation de fusions de peptides/protéines de transthyrétine pour augmenter la demi-vie sérique de peptides/protéines pharmacologiquement actifs
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
DK1412503T3 (da) Et fusionsprotein
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
WO2003022883A3 (fr) Utilisation d'une proteine pour preparer un medicament servant a stimuler le systeme immunitaire inne non specifique
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2003280359A1 (en) Phosphoamidase assay
WO2003048320A3 (fr) Nouvelle proteine moteur de p. falciparum et methodes d'utilisation de cette derniere